BETHESDA, Md., May 28, 2015 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has filed an exclusive patent application with the US Patent & Trademark Office (USPTO) on a System and Method for High Throughput Screening of Cancer Cells.
Cannabics' team of scientists has developed a high throughput screening system which is specifically designed to give personalized antitumor treatments to cancer patients. In this proprietary system, biopsies are treated, in-vitro, with innumerous plant extract combinations and the antitumor effects are screened and calculated. The results could enable cancer patients to receive cannabinoid based therapy with a potential of reducing their tumors. Cannabics Pharmaceuticals plans to complete the development of this novel and sophisticated technology and license it by the end of 2016.
Dr. Eyal Ballan, Chief Scientist of the company said," Cannabinoids are known for their antitumor properties, and this natural personalized therapy could be highly effective and without side effects, thus benefiting millions of patients worldwide."
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on April 20th, 2015. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
About Cannabics Pharmaceuticals Inc.
Cannabics Pharmaceuticals (OTC: CNBX) is a US public company with Research & Development conducted in Israel. Cannabics is engaged in the development and commercialization of cannabinoid based medicine upon the wide range of active ingredients found in diverse strains of cannabis. The company's main focus is standardized oral delivery systems, personalized cancer therapies and procedures based on novel biotechnology tools and bioinformatics. For more information, visit www.Cannabics.com.
For Further Information, please contact:
Cannabics Pharmaceuticals, Inc.
SOURCE Cannabics Pharmaceuticals Inc.